everolimus
Not Tagged
['renal,(-adrenal)', 'rcc,(-irccs),(-srcc),(-urcc)', 'everest', 'everolimus']
results from the phase 3 everest trial presented during 2022 reveal the relapse-free survival advantage of using adjuvant everolimus over placebo in patient with high-risk renal cell carcinoma. #asco22 #rcc 
Oncology news and insights from leading researchers and cancer centers.